DNLI vs DVA: fair value comparison
Denali Therapeutics Inc. and DaVita Inc. · Updated 2026-10-19
DNLI has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, DNLI currently ranks higher by quality score.
| DNLI | DVA | |
|---|---|---|
| Verdict | No estimate yet | Undervalued |
| Last price | $17.61 | $179.25 |
| 12-month range | $14.41–$27.21 | $103.87–$240.96 |
| Rank by discount to fair value | — | #29 of 108 Healthcare |
| Rank by quality score | #99 of 301 Healthcare | #100 of 301 Healthcare |
| Quality grade | C | C |
| Leverage | Low | Low |
| Margin trend | Stable | Contracting |
| Revenue growth | High | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | — |
| DCF cross-check | — | Undervalued |
| 52-week position | The bottom quarter | The upper-middle quarter |
Full single-stock breakdowns: DNLI fair value analysis · DVA fair value analysis